Navigation Links
Northfield Laboratories Reports Results of Pivotal Phase III Trauma,Study

k following traumatic injuries beginning in the prehospital setting. Treatment began at the scene of injury, continued in the ambulance during transport, and for up to 12 hours post-injury or a total of 6 units. Patients then received donated blood if they continued to bleed. Patients in the control group received the standard of care: saline in the field and during transport, followed by blood upon arrival at the hospital. Thirty-two Level I trauma centers participated in the study, which was conducted to seek an indication for the use of PolyHeme that addresses a critical, unmet medical need: the unavailability of blood.

In December 2006, Northfield announced that it had received the preliminary draft top-line data from its contract research organization. Northfield indicated that due to certain discrepancies in the data identified during its initial review, it became necessary to resolve the discrepancies and unlock the study database to make any necessary corrections. The process has now been completed, the study database relocked, and the data reanalyzed. Northfield has also had the opportunity to further analyze the study data, including additional safety data. These data have not been submitted to or reviewed by FDA.

About Northfield Laboratories

Northfield Laboratories, Inc., is a leader in developing an oxygen-carrying red blood cell substitute for the treatment of life-threatening blood loss, when an oxygen-carrying fluid is required and red blood cells are not available. PolyHeme(R) is a solution of chemically modified human hemoglobin that requires no cross matching and is, therefore, compatible with all blood types. It has a shelf life in excess of 12 months. For further information, visit www.northfieldlabs.com.

Forward Looking Statement

This press release may contain forward-looking statements concerning, among other things, Northfield's future business plans and strategies and clinical and regulatory developments af
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Northfield Laboratories Investor Update
2. Columbia Laboratories Reports Positive Results from Multi-dose Pharmacokinetic Study of Vaginally-administered Lidocaine
3. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study for Milnacipran as a Treatment for Fibromyalgia Syndrome
4. Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth
5. Corgenix Reports New Clinical Data Correlating AtherOx Technology With Vascular Disease
6. Cobalis Reports Phase III Trial Results for PreHistin in Seasonal Allergic Rhinitis
7. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
8. Cytos Biotechnology Reports Results from Phase IIa Study with CYT003-QbG10 in Patients Suffering from Atopic Dermatitis
9. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. Cytochroma Reports Positive Phase I Clinical Data for CTA018 Injection
Post Your Comments:
(Date:8/27/2015)... CHICAGO , Aug. 27, 2015  Hill-Rom Holdings, ... to a management presentation at the Morgan Stanley Global ... ET. You are invited to listen to ... http://ir.hill-rom.com/events.cfm  or access it directly at https://cc.talkpoint.com/morg007/091615a_ae/?entity=49_UCJPU8N . ... be available one hour after the conclusion of the ...
(Date:8/27/2015)... pharmaceutical and medical device companies and leading law firms will ... on Oct. 20, discussing issues surrounding regulatory compliance, ... Litigation Conferences has announced. To learn more ... The program is co-chaired by Megan Grossman ... Hart Yeary of Dechert LLP. Topics include: ...
(Date:8/27/2015)... , August 27, 2015 ... announced a private investment in public equity (PIPE) deal, ... $28.4 million in Itamar Medical.   Through ... shareholder of Itamar Medical and will work closely with ... According to the investment agreement, Itamar Medical ...
Breaking Medicine Technology:Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 2Pharmaceutical, Medical Device Law Seminar Features In-House, Outside Counsel 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 2Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 3Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 4Viola Private Equity Invests up to $28.4 Million in Itamar Medical and Becomes the Largest Shareholder of the Company 5
... 20, 2011 Comprehensive Care Corporation (OTC BB: CHCR), ... management services for managed care companies throughout the U.S., ... has been praised by the Chamber of Commerce of ... Leadership Advisory Council in "helping to shape and drive ...
... YDNT ) today announced record earnings per share for ... ended September 30, 2011. Sales for the third quarter ... $26.4 million reported for the third quarter of 2010. Income from ... $6.1 million in the prior year quarter. Net income for the ...
Cached Medicine Technology:Comprehensive Care Corporation CEO Clark A. Marcus Praised for U.S. Chamber of Commerce Service 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 2Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 3Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 4Young Innovations, Inc. Announces Record EPS for the Quarter and Record Sales and EPS for the Nine-Months Ended September 30, 2011 and Declares Quarterly Dividend 5
(Date:8/27/2015)... Yardley, Penn. (PRWEB) , ... August 27, 2015 ... ... engagement solutions, confirmed today that its Krames Patient Education content is ICD-10 ready ... and is ready for the new ICD-10 code sets, which are more targeted ...
(Date:8/27/2015)... ... August 27, 2015 , ... More destinations and stores are becoming pet-friendly, ... Amica Insurance is sharing some tips to help your whole family travel safely and ... travel with pets each year. Amica is sharing the following tips from the American ...
(Date:8/27/2015)... and OKLAHOMA CITY, OK (PRWEB) , ... August ... ... Point Partners (“GPP”) I, LP portfolio company and leading biopharmaceutical contract development manufacturing ... be acquired by Hepalink USA Inc. (“Hepalink”) for $205.68M in cash. ...
(Date:8/27/2015)... ... 27, 2015 , ... Florida Hospital North Pinellas, located at 1395 South Pinellas Avenue in Tarpon ... The new facility will be located at US Highway 19 North and Highlands Boulevard, less ... 18, and work on the project is slated to begin in September 2015. ...
(Date:8/27/2015)... Collegedale, Tennessee (PRWEB) , ... August 27, 2015 , ... ... preservatives or high fructose corn syrup, is changing the expectation of how protein bars ... a rich, indulgent taste unlike any other protein bar on the market today. ...
Breaking Medicine News(10 mins):Health News:StayWell announces all health content is ICD-10 ready 2Health News:StayWell announces all health content is ICD-10 ready 3Health News:Amica Unleashes 5 Tips for Safe Traveling with Pets 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 2Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 3Health News:Great Point Partners, LLC Announces that Hepalink USA Inc. Agrees to Acquire Cytovance Biologics, Inc. 4Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 2Health News:Florida Hospital North Pinellas is Opening a New Free-Standing Emergency Room in Palm Harbor 3Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 2Health News:Sunbelt® Bakery Changes the Expectations of How Protein Bars Should Taste with the Introduction of Its New Protein Delights 3
... from having problems paying medical bills, and having bill problems ... medicines, a new study has found. According to a ... Journal of Public Health , after taking age, income and ... the odds of accruing debt related to medical care or ...
... Alan Mozes HealthDay Reporter , THURSDAY, June 16 ... habits of America,s teens, new data from the U.S. Centers ... Not only are high school kids guzzling far too ... CDC research team found. In fact, just one in ...
... pilot study of etanercept for treatment of dermatomyositis found ... the drug were successfully weaned from steroid therapy. These ... further investigate the safety and efficacy of etanercept. Results ... of Neurology , a journal published by Wiley-Blackwell on ...
... new study published today in the journal Child ... a poor "gut sense" of numbers can lead to ... math proficiency. This inaccurate number sense is just one ... led by Dr. Michele Mazzocco of the Kennedy Krieger ...
... UT Southwestern Medical Center scientists are shedding new ... fast-acting antidepressant response in patients with treatment-resistant depression. ... as a fast-acting antidepressant potentially has use in emergency ... very sharp increase that immediately relieves depression," said Dr. ...
... of death across a population has evolved in recent ... heart attack and cancer, the role of behavioral factorsincluding ... the 1990s. More recent research has begun to ... mortality. In the first comprehensive analysis of such studies, ...
Cached Medicine News:Health News:Medical debt occurs despite insurance, UA study shows 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 2Health News:High School Kids Get Too Many Sugary Drinks, Too Little Exercise: CDC 3Health News:Etanercept shows promise for treating dermatomyositis 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 2Health News:Poor 'gut sense' of numbers contributes to persistent math difficulties 3Health News:How many US deaths are caused by poverty, low levels of education and other social factors? 2
The VascoTip J 9/60 PU is a unipolar tined, J-preformed permanent pacing lead. Due to advanced technology, VascoTip J 9/60 PU M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm),...
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
VascoTip is a unipolar tined permanent pacing lead. Due to advanced technology, VascoTip 9/60 M is compatible to all pacemaker-cavities with the size of IS-1 (3.2 mm), 5 mm, 6 mm....
Medicine Products: